Baird raised the firm’s price target on Inspire Medical (INSP) to $180 from $125 and keeps an Outperform rating on the shares. The firm updated its model following its meetings with management.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
- Inspire Medical downgraded to Equal Weight at Morgan Stanley on slowing growth
- Inspire Medical downgraded to Equal Weight from Overweight at Morgan Stanley
- Truist upgrades Inspire Medical to Buy after positive reimbursement ‘surprise’
- Inspire Medical upgraded to Buy from Hold at Truist